Yulia Mikhailovna Zabrodskaya

Yulia Mikhailovna Zabrodskaya

Auto-generated profile, based on publicly available information

Yulia Mikhailovna Zabrodskaya

Polenov Neurosurgery Institute – the branch of Almazov National Medical Research Centre

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2022 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
KKK. K. Kukanov
K. K. Kukanov
OVO. M. Vorobyova
O. M. Vorobyova
YZYu. M. Zabrodskaya
Yu. M. Zabrodskaya
EPE. G. Potemkina
E. G. Potemkina
VUV. V. Ushanov
V. V. Ushanov
NIN. E. Ivanova
N. E. Ivanova
Introduction. Meningiomas are the second most common central nervous system (CNS) tumors in adults. most meningiomas are benign tumors. Anaplastic and atypical meningiomas account for 25% and have a high recurrence rate even after radical tumor resection and radiotherapy. The prognosis of patients with anaplastic meningiomas remains disappointing; most of them die within the first 2 to 5 years after surgery. Purpose: to discuss the challenges in diagnosis and treatment of recurrent meningiomas, to identify the causes of tumor progression, and to assess the clinical features and radiographic findings as well as specific pathomorphological and molecular genetic characteristics. material and methods. We searched for publications in the Pubmed, EMBASE, Cohrane Library and eLibrary databases published between January 2000 and January 2019 on the issue of recurrent intracranial meningiomas, in particular atypical and anaplastic meningiomas. Results. The review systematizes data on the prognostic factors for survival, relapse-free period, and disease progression. particular attention was paid to the radical resection of the tumor and the assessment of the grade of anaplasia. The current data on radiotherapy and drug therapy were presented. the controversial issues of approaches to the assessment of morphological prognostic criteria were discussed. The current knowledge on the most common genetic mutations in meningiomas, the prospects for their study and use for targeted therapy were presented. Conclusion. The management of meningioma still presents some unresolved issues. There are no optimal standards for diagnosis and treatment of patients with meningiomas that would take into account biological characteristics, including growth characteristics and molecular genetic profile. There are no clear prognostic criteria for recurrence and continuity in further management after surgical treatment, which affects the mortality rate and quality of life in this category of patients. New fundamental data that will determine a different strategy in the treatment of intracranial meningiomas are needed.

13 February 2023 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
ARArtemii Yuryevich Rynda
Artemii Yuryevich Rynda
VOV.E. Olyushin
V.E. Olyushin
DRD.M. Rostovtsev
D.M. Rostovtsev
YZYu.M. Zabrodskaya
Yu.M. Zabrodskaya
AUA.YU. Ulitin
A.YU. Ulitin
GPG.V. Papayan
G.V. Papayan
Лечение злокачественных глиом — экстремально сложная задача, зачастую с трудным выбором тактики. Фотодинамическая терапия до сих пор не является стандартом в помощи таким пациентам, несмотря на то, что результаты использования данной методики в хирургии глиом доказывают статистически значимое улучшение результатов лечения. ЦЕЛЬ ИССЛЕДОВАНИЯ Продемонстрировать возможности фотодинамической терапии злокачественных глиальных опухолей с использованием хлорина E6. МАТЕРИАЛ И МЕТОДЫ В исследование вошел 161 пациент со злокачественной глиальной опухолью супратенториальной локализации, находившийся на лечении в РНХИ им. проф. А.Л. Поленова с 2009 по 2016 г. Из них 80 больных составили основную группу (с фотодинамической терапией), 81 — группу сравнения (без фотодинамической терапии). РЕЗУЛЬТАТЫ Фотодинамическая терапия в структуре комплексной терапии злокачественных глиом головного мозга достоверно увеличивает медиану общей выживаемости у пациентов с grade III глиомами до 39,1±5,5 мес (основная группа — 22,8±3,3 мес), grade IV глиомами — до 20,7±4,7 мес (группа сравнения — 13,5±2,3 мес) (p=0,0002); а также и величину межрецидивного периода для пациентов с grade III глиомами — до 21,7±3,4 месяцев (основная группа — 15,8±3,1 мес) (p=0,0002); с grade IV глиомами — до 11,1±2,1 мес (группа сравнения — 8,0±2,3 мес) (p=0,0001).

Verified
Journal Article
Open access
PDF file
YZYulia Zabrodskaya
Yulia Zabrodskaya
NPNatalia Paramonova
Natalia Paramonova
Anastasia LitovchenkoAnastasia Litovchenko
Anastasia Litovchenko
Elena D. BazhanovaElena D. Bazhanova
Elena D. Bazhanova
AGAlexander Pavlovich Gerasimov
Alexander Pavlovich Gerasimov
KSKonstantin Samochernykh
Konstantin Samochernykh
Drug-resistance epilepsy (DRE) is a key problem in neurology. It is possible that damage to the blood–brain barrier (BBB) may affect resistance in DRE. The aim of this work was to assess the damage and dysfunction in the BBB in the area of epileptic foci in patients with DRE under conditions of neuroinflammation. The changes to the BBB in temporal lobe epilepsy (by immunohistochemistry and transmission electron microscopy), levels of neuroinflammatory proteins, and cytokine levels in the blood (by multiplex analysis) were studied. Increased levels of vascular endothelial growth factor (VEGF) and growth-regulated protein (GRO), and decreased levels of epidermal growth factor (EGF) in plasma, combined with overexpression of the VEGF-A receptor by endotheliocytes were detected. Malformation-like growths of the basement membrane of the capillaries of the brain complicate the delivery of antiepileptic drugs (AEDs). Dysplasia of the basement membrane is the result of inadequate reparative processes in chronic inflammation. In conclusion, it should be noted that damage to the microcirculatory network of the brain should be considered one of the leading factors contributing to DRE.

16 January 2024 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
ARArtemii Yuryevich Rynda
Artemii Yuryevich Rynda
DRDmitrii M. Rostovthev
Dmitrii M. Rostovthev
YZYulia M. Zabrodskaya
Yulia M. Zabrodskaya
VOVictor E. Olyushin
Victor E. Olyushin

1 January 2022 in Pirogov Russian Journal of Surgery
Verified
Journal Article
Closed access
ARArtemii Yuryevich Rynda
Artemii Yuryevich Rynda
VOV.E. Olyushin
V.E. Olyushin
DRD.M. Rostovtsev
D.M. Rostovtsev
YZYu.M. Zabrodskaya
Yu.M. Zabrodskaya
GPG.V. Papayan
G.V. Papayan
Метаболическая навигация в хирургии злокачественных глиом — наиболее эффективный способ, позволяющий различить во время операции границу опухоли, достичь более радикальной резекции и, как следствие, увеличить межрецидивный интервал и продолжительность жизни. ЦЕЛЬ ИССЛЕДОВАНИЯ Сравнительный анализ специфичности и чувствительности метода флуоресцентной навигации в хирургии злокачественных глиом с использованием двух различных индукторов флуоресценции. МАТЕРИАЛ И МЕТОДЫ Проведен сравнительный анализ флуоресцентной навигации у 50 пациентов (2 группы) с глиомой высокой степени анаплазии, находившихся на лечении в отделении нейроонкологии РНХИ им. проф. А.Л. Поленова. У 25 пациентов (1-я группа) в качестве индуктора флуоресценции использовали хлорин Е6 1 мг/кг внутривенно (фотодитазин), другие 25 пациентов (2-я группа) получили 5-аминолевулиновую кислоту (5-АЛА) перорально 20 мг/кг (аласенс). В каждой группе были 10 пациентов с анаплазией глиомы grade III и 15 пациентов с анаплазией grade IV. Обе группы статистически репрезентативны (p>0,05). РЕЗУЛЬТАТЫ Для хирургии глиом grade III чувствительность метода составила 83,8% (хлорин E6), 82,5% (5-АЛА), специфичность — соответственно 66,7% и 64,1%. Для хирургии глиом grade IV чувствительность метода составила 87,7% (хлорин E6), 88,3% (5-АЛА), специфичность — соответственно 85,2% и 88,1%. ЗАКЛЮЧЕНИЕ Статистический анализ показал сопоставимую высокую эффективность препаратов в хирургии злокачественных глиом. Чувствительность и специфичность метода для флуоресцентных препаратов хлорин E6 и 5-АЛА не показали статистически значимой разницы в достижении результата (p>0,05).

23 April 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
ARArtemii Yuryevich Rynda
Artemii Yuryevich Rynda
VOV.E. Olyushin
V.E. Olyushin
DRD.M. Rostovtsev
D.M. Rostovtsev
KKK.K. Kukanov
K.K. Kukanov
SSS.S. Sklyar
S.S. Sklyar
YZYu.M. Zabrodskaya
Yu.M. Zabrodskaya
Objective. Analysis of long-lived patients from the group of patients with glioblastomas after using photodynamic therapy in the structure of their complex treatment in order to assess the influence of various factors on their life expectancy. Material and methods. In total, a single-center, retrospective categorical study analyzed the long-term results of treatment of 63 patients with glioblastoma in the structure of complex treatment including photodynamic therapy. Clinical factors (age, sex, number of cases, preoperative Karnofsky index, location and size of the tumor, radicality of the operation), histological (nuclear polymorphism, mitosis, vascular proliferation, necrosis), immunohistochemical (Ki-67, p53 index) molecular-genetic factors (expression of VEGF, MGMT, IDH, CD34), amount of radiation and chemotherapy were analyzed. Results. In the entire group of patients, there was a direct correlation of life expectancy with MGMT status, IDH status, the number of courses of chemotherapy, the age of the patient, and the severity of the first surgical intervention. Conclusion. Clinical features such as age at diagnosis and extent of surgical resection and amount of chemotherapy have predictive value in assessing their effect on life expectancy. Mutations in IDH and MGMT promoter methylation were the most important molecular factors determining long-term patient survival.